Market›Health Care›Pharmaceuticals›Pharmaceuticals
PROCESSA PHARMACEUTI

PCSA

$2.98Apr 26, 2021 – Apr 24, 2026
Health CarePharmaceuticals$8M
MVM
-$0.1M
TD Variance
-0.564

Every news event mapped to its market reaction — 146 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2024-01-25+78.6%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2025-10-07+71.5%newsChartMillThese stocks are making the most noise in today's session. - ChartMill
2025-10-07+71.5%newsChartMillStay updated with the stocks that are on the move in today's pre-market session. - ChartMill
2025-10-07+71.5%newsBenzingaWhy Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga
2025-12-15-55.1%newsInvesting.comProcessa Pharmaceuticals announces 1-for-25 reverse stock split effective this week - Investing.com
2024-01-26-46.2%newsSeeking AlphaProcessa Pharmaceuticals prices discounted stock and warrants offering to raise $7M
2025-12-18-44.8%earningsYahoo FinancePCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study - Yahoo Finance
2025-12-18-44.8%newsZacks Investment ResearchShould I buy Heatwurx (PCSA) - Zacks Investment Research
2025-12-18-44.8%newsChartMillDiscover the top movers in Thursday's pre-market session. - ChartMill
2025-12-18-44.8%newsChartMillThere are notable gap-ups and gap-downs in today's session. - ChartMill
2024-01-19-39.8%newsSeeking AlphaProcessa stock rallies on NGC-Cap development update
2025-06-13-34.4%newsGuruFocusProcessa Pharmaceuticals (PCSA) Prepares for Strategic Insights at BIO Convention 2025 | PCSA Stock News - GuruFocus
2024-04-25+32.2%newsSeeking AlphaPOET, PCSA and BRFH are among premarket gainers
2025-12-17+30.4%newsYahoo FinanceWill Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely? - Yahoo Finance
2025-12-17+30.4%newsStock TitanEarly breast cancer trial tests drug mix for more impact, similar side effects - Stock Titan
2025-12-17+30.4%newsInvesting.comProcessa Pharmaceuticals stock soars after cancer drug shows promising results - Investing.com
2025-12-17+30.4%newsMSNWhy did Processa Pharmaceuticals stock surge 160% today? - MSN
2025-12-17+30.4%newsStocktwitsWhy Did Processa Pharmaceuticals Stock Surge 160% Today? - Stocktwits
2025-12-17+30.4%newsBenzingaWhy Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data? - Benzinga
2025-12-17+30.4%newsQuiver QuantitativeProcessa Pharmaceuticals Reports Promising Preliminary Phase 2 Data for NGC-Cap Combination Therapy in Advanced Breast Cancer - Quiver Quantitative
2025-12-17+30.4%newsStocktwitsOracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today - Stocktwits
2025-12-17+30.4%newsTrefisMarket Movers | Winners: TTSH, PCSA, STAI | Losers: ZYXI, DFLI, IRBT - Trefis
2023-11-13+29.5%legalSEC EDGARPCSA 8-K: 5.02 and (SEC Filing)
2026-03-19-24.6%newsTrefisMarket Movers | Winners: ORGN, CIIT, SER | Losers: RVPH, SBDS, CREG - Trefis
2026-03-18-24.6%earningsTradingViewProcessa Pharmaceuticals 2025 10-K: $0 revenue, $(10.36) EPS on $(13.56)M net loss - TradingView
2025-06-18+23.6%legalSEC EDGARPCSA 8-K: 1.01, 7.01 (SEC Filing)
2024-07-30+22.4%legalSeeking AlphaFDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46%
2024-07-30+22.4%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2023-12-13-20.8%newsSeeking AlphaProcessa falls after update on chemotherapy development
2023-12-13-20.8%legalSeeking AlphaProcessa stock falls after FDA views on chemotherapy trial - Seeking Alpha
2024-01-18-19.4%newsSeeking AlphaProcessa Pharmaceuticals to effect 1-for-20 reverse stock split to regain compliance with Nasdaq rule
2022-07-25-15.9%legalSEC EDGARPCSA 8-K: 5.02 and (SEC Filing)
2022-05-13-15.8%earningsSeeking AlphaProcessa Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
2026-04-17-15.8%executiveStock TitanProcessa Pharmaceuticals (NASDAQ: PCSA) R&D chief buys 1,545 shares in open market - Stock Titan
2026-04-17-15.8%executiveInvesting.comLin Patrick, Processa Pharma chief, buys $4,065 in PCSA stock - Investing.com
2026-04-17-15.8%executiveInvesting.comProcessa Pharma CFO Skibsted buys $5892 in PCSA stock - Investing.com
2026-04-17-15.8%executiveStock TitanProcessa (PCSA) strategy chief buys 1,369 shares at $2.97 - Stock Titan
2026-04-17-15.8%newsStock TitanProcessa (PCSA) CDO buys 1,799 company shares in open market - Stock Titan
2026-04-17-15.8%newsStock TitanProcessa (NASDAQ: PCSA) CAO Wendy Guy buys 1,583 shares in open market - Stock Titan
2026-04-17-15.8%executiveStock TitanProcessa Pharmaceuticals (PCSA) CEO adds 1,843 shares in open-market buy - Stock Titan
2026-04-17-15.8%executiveStock TitanProcessa (NASDAQ: PCSA) CFO adds 1,984 shares in open-market buy - Stock Titan
2026-04-17-15.8%executiveInvesting.comWendy Guy, chief administrative officer, buys $4,701 in Processa Pharma (PCSA) - Investing.com
2026-04-17-15.8%executiveInvesting.comProcessa Pharma CEO Ng buys $5.5k in shares - Investing.com
2026-04-17-15.8%executiveInvesting.com IndiaProcessa Pharma CFO Skibsted buys $5892 in PCSA stock By Investing.com - Investing.com India
2026-04-17-15.8%executiveInvesting.com AustraliaProcessa Pharma CFO Skibsted buys $5892 in PCSA stock By Investing.com - Investing.com Australia
2026-04-17-15.8%executiveInvesting.comBigora Sian, chief development officer, buys Processa shares - Investing.com
2026-04-17-15.8%newsInvesting.com South AfricaProcessa Pharma director Young buys shares worth $4,588 By Investing.com - Investing.com South Africa
2026-04-17-15.8%executiveInvesting.com South AfricaBigora Sian, chief development officer, buys Processa shares By Investing.com - Investing.com South Africa
2026-04-17-15.8%executiveInvesting.com UKProcessa Pharma CEO Ng buys $5.5k in shares By Investing.com - Investing.com UK
2026-04-17-15.8%executiveInvesting.com CanadaProcessa Pharma CEO Ng buys $5.5k in shares By Investing.com - Investing.com Canada
2026-04-17-15.8%executiveInvesting.com CanadaBigora Sian, chief development officer, buys Processa shares By Investing.com - Investing.com Canada
2026-04-17-15.8%executiveInvesting.com UKBigora Sian, chief development officer, buys Processa shares By Investing.com - Investing.com UK
2026-01-05+14.1%newsStock TitanNew combo cancer drug reaches key test in advanced breast cancer trial - Stock Titan
2022-06-02+13.8%newsSeeking AlphaProcessa Pharmaceuticals (PCSA) Investor Presentation - Slideshow
2023-02-06-13.5%legalSEC EDGARPCSA 8-K: 8.01 (SEC Filing)
2024-01-30-13.4%legalSEC EDGARPCSA 8-K: 1.01, 7.01 (SEC Filing)
2026-04-21+12.9%newsChartMillPCSA Stock Price, Quote & Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
2023-11-03+12.6%earningsTradingViewProcessa Pharmaceuticals, Inc. Earnings and Revenue – NASDAQ:PCSA - TradingView
2026-04-18-12.4%M&AGuruFocusInsider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
2026-04-18-12.4%newsInvesting.com AustraliaProcessa Pharma director Young buys shares worth $4,588 By Investing.com - Investing.com Australia
2024-10-31-12.0%earningsSeeking AlphaProcessa Pharmaceuticals GAAP EPS of -$1.03
2026-01-09-10.1%newsACCESS NewswireAlliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
2026-04-20-10.0%newsCổng thông tin điện tử tỉnh Lào CaiIs Processa Pharmaceuticals (PCSA) stock testing important levels (Pressure Mounts) 2026-04-20 - Wall Street Picks - Cổng thông tin điện tử tỉnh Lào Cai
2025-01-30+9.8%legalSEC EDGARPCSA 8-K: 1.01, 7.01 (SEC Filing)
2024-01-12-9.4%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2025-10-08+8.9%newsBenzingaWhy Processa Pharmaceuticals Stock Rose Almost 38% Overnight? - Processa Pharma (NASDAQ:PCSA) - Benzinga
2026-04-01+8.9%newsStock TitanProcessa (NASDAQ: PCSA) CDO buys 2,107 shares in open-market trade - Stock Titan
2026-04-01+8.9%executiveInvesting.comNg George K, Processa Pharma CEO, buys PCSA stock worth $5414 - Investing.com
2026-04-01+8.9%executiveInvesting.comRussell Skibsted, CFO, buys Processa Pharma (PCSA) shares worth $5,891 - Investing.com
2026-04-01+8.9%newsInvesting.comProcessa Pharma director Pannu buys $5,252 in PCSA stock - Investing.com
2026-04-01+8.9%newsStock TitanDirector adds 2,269 Processa (PCSA) shares at $2.535 each - Stock Titan
2026-04-01+8.9%newsStock Titan[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
2026-04-01+8.9%executiveStock TitanProcessa Pharmaceuticals (NASDAQ: PCSA) CFO buys 2,324 company shares - Stock Titan
2026-04-01+8.9%newsInvesting.comYoung David, processa pharma pres, buys PCSA shares worth $4588 - Investing.com
2026-04-01+8.9%newsStock TitanProcessa Pharmaceuticals (PCSA) CAO buys 1,854 shares in open trade - Stock Titan
2026-04-01+8.9%newsStock TitanProcessa Pharmaceuticals (PCSA) officer adds 1,603-share open-market buy - Stock Titan
2026-04-01+8.9%newsInvesting.comBaluch Khoso buys Processa Pharmaceuticals (PCSA) shares worth $5751 - Investing.com
2025-06-17+8.4%legalSEC EDGARPCSA 8-K: 1.01, 7.01 (SEC Filing)
2025-06-17+8.4%newsYahoo FinanceProcessa Pharmaceuticals Announces Pricing of $7 Million Public Offering - Yahoo Finance
2025-06-17+8.4%M&AStock Titan$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan
2025-06-17+8.4%newsGuruFocusProcessa Pharmaceuticals (PCSA) Sets Public Offering Price at $0 - GuruFocus
2025-06-17+8.4%newsGlobeNewswireProcessa Pharmaceuticals Announces Pricing of $7 Million Public Offering - GlobeNewswire
2025-07-01-8.2%legalSEC EDGARPCSA 8-K: 1.01, 7.01 (SEC Filing)
2025-07-25-8.0%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2025-07-25-8.0%legalStock Titan[424B5] Processa Pharmaceuticals, Inc. Common Prospectus Supplement (Debt Securities) - Stock Titan
2021-08-20+7.2%legalSEC EDGARPCSA 8-K: 1.01 and (SEC Filing)
2026-04-02+7.0%newsStock TitanDirector Neal James R adds Processa (PCSA) shares in open trade - Stock Titan
2025-07-11-6.8%analystYahoo FinanceProcessa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress - Yahoo Finance
2022-05-14-6.8%earningsSeeking AlphaProcessa Pharmaceuticals' (PCSA) CEO David Young on Q1 2022 Results - Earnings Call Transcript
2021-08-13-6.2%legalSEC EDGARPCSA 8-K: 2.02 and (SEC Filing)
2026-03-16+5.8%earningsTradingViewProcessa Pharmaceuticals Inc expected to post a loss of $1.50 a share - Earnings Preview - TradingView
2023-05-12-5.7%newsBenzingaProcessa Pharma Insider Trading Activity | NASDAQ:PCSA - Benzinga
2025-02-10-5.5%newsInvesting.comProcessa Pharmaceuticals faces Nasdaq delisting risk over share price - Investing.com
2023-02-13+5.4%legalSEC EDGARPCSA 8-K: 1.01, 7.01 (SEC Filing)
2025-08-06-5.2%newsYahoo FinanceInsider Stock Buyers At Processa Pharmaceuticals Recouped Some Losses This Week - Yahoo Finance
2022-07-14-5.2%legalSEC EDGARPCSA 8-K: 5.02, 5.07 (SEC Filing)
2024-05-21-5.1%newsSeeking AlphaProcessa Pharmaceuticals files for $50M mixed shelf
2024-05-21-5.1%legalSEC EDGARPCSA 8-K: 1.01 and (SEC Filing)
2025-08-14-5.0%legalSEC EDGARPCSA 8-K: 1.01, 3.02, 7.01 (SEC Filing)
2023-08-08-5.0%executiveSeeking AlphaProcessa Pharmaceuticals appoints George Ng as CEO
2023-08-08-5.0%legalSEC EDGARPCSA 8-K: 5.02, 7.01 (SEC Filing)
2022-11-04-4.7%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2025-04-22+4.4%newsIntellectia AIPCSA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
2024-07-17-4.1%executiveSeeking AlphaProcessa Pharmaceuticals appoints CFO
2024-07-17-4.1%legalSEC EDGARPCSA 8-K: 5.02, 7.01 (SEC Filing)
2026-01-12-4.1%newsStock TitanBreast cancer trial data in focus as Processa joins major health event - Stock Titan
2022-04-20-4.1%newsSeeking AlphaProcessa begins dosing in phase 1b trial of chemotherapy combo for gastrointestinal cancer
2025-08-08-4.0%earningsTradingViewProcessa Pharmaceuticals Inc prevede una perdita di 12 centesimi per azione - Earnings Preview - TradingView
2024-02-06-3.7%newsSeeking AlphaProcessa Pharmaceuticals regains compliance with Nasdaq minimum bid price rule
2024-02-06-3.7%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2025-04-24-3.7%newsStock TitanPCSA Stock Price, News & Analysis - Stock Titan
2025-01-28-3.7%newsSeeking AlphaProcessa Pharmaceuticals prices $5M equity offering
2024-08-28-3.6%earningsSeeking AlphaProcessa Pharmaceuticals reports GAAP EPS of -$1.01
2024-08-28-3.6%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2022-03-24-2.9%legalSEC EDGARPCSA 8-K: 1.01 and (SEC Filing)
2026-01-08-2.8%newsThe Globe and MailProcessa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance - The Globe and Mail
2022-05-16+2.8%legalSEC EDGARPCSA 8-K: 8.01 (SEC Filing)
2025-08-25+2.8%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2026-01-07+2.7%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2023-02-10-2.7%newsSeeking AlphaProcessa extends losses after $6M stock offering
2022-12-14+2.5%newsSeeking AlphaProcessa jumps 11% after mid-stage data for gastroparesis candidate
2025-05-02-2.5%newsTradingKeyPCSA|Processa Pharmaceuticals Inc|Price:2.980|Chg%:-0.01 - TradingKey
2021-05-13-2.1%legalSEC EDGARPCSA 8-K: 2.02 and (SEC Filing)
2025-06-30+1.6%legalSEC EDGARPCSA 8-K: 1.01, 5.07 (SEC Filing)
2022-08-12+1.5%earningsSeeking AlphaProcessa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73
2022-08-12+1.5%legalSEC EDGARPCSA 8-K: 2.02 and (SEC Filing)
2022-11-08-1.3%earningsSeeking AlphaProcessa Pharmaceuticals GAAP EPS of -$0.90 for 9M
2022-11-08-1.3%legalSEC EDGARPCSA 8-K: 2.02, 7.01 (SEC Filing)
2024-10-02-1.3%newsSeeking AlphaProcessa stock rallies 35% post-market on Phase 2 study update
2024-10-02-1.3%legalSEC EDGARPCSA 8-K: 8.01 and (SEC Filing)
2025-06-04+1.2%newsIntellectia AIPCSA Forecast — Price Prediction for 2026. Should I Buy PCSA? - Intellectia AI
2022-05-12-1.2%earningsSeeking AlphaProcessa Pharmaceuticals Non-GAAP EPS of -$0.20
2025-08-07+1.1%legalSEC EDGARPCSA 8-K: 1.01, 3.02, 7.01 (SEC Filing)
2025-08-07+1.1%legalQuiver QuantitativeProcessa Pharmaceuticals Secures Strategic Investment and Explores Cryptocurrency Treasury Strategies for Long-Term Growth | PCSA Stock News - Quiver Quantitative
2022-03-31+0.9%newsSeeking AlphaProcessa Pharmaceuticals (PCSA) Investor Presentation - Slideshow
2022-03-31+0.9%earningsSeeking AlphaProcessa Pharmaceuticals' (PCSA) CEO David Young on Q4 2021 Results - Earnings Call Transcript
2022-03-30+0.8%earningsSeeking AlphaProcessa Pharmaceuticals GAAP EPS of -$0.75 misses by $0.01
2022-08-14+0.8%earningsSeeking AlphaProcessa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q2 2022 Results - Earnings Call Transcript
2023-03-31-0.8%earningsSeeking AlphaProcessa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript
2023-03-31-0.8%legalSEC EDGARPCSA 8-K: 2.02, 7.01 (SEC Filing)
2022-11-13+0.4%earningsSeeking AlphaProcessa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcript
2022-11-13+0.4%earningsSeeking AlphaProcessa Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
2021-11-20+0.3%newsStockInvest.usPCSA Insider Trading (Processa Pharmaceuticals Inc. stock) - StockInvest.us
2021-06-17+0.0%legalSEC EDGARPCSA 8-K: 1.01, 7.01 (SEC Filing)
2026-04-27—newsMSNPCSA stock rallies 10% after hours—here’s why - MSN
2026-04-24—newsValue ResearchProcessa Pharmaceuticals Inc. (PCSA) Share Price Today | Processa Pharmaceuticals (PCSA) Live NSE/BSE - Value Research
tickerdossier.comtickerdossier.substack.com